- Published on
Pathology - Myelodysplastic syndromes
Definition: A collection of hematopoietic neoplasms distinguished by dysplasia in one or more myeloid cell lineages, accompanied by inefficient myelopoiesis, cytopenias, and an elevated risk of acute myeloid leukemia (AML) development.
Epidemiology • Estimated yearly incidence ranges from 3 to 5 per 100,000 individuals. • Predominantly affects older adults, with a median age of 70 years.
Aetiology • Predominantly unknown in the majority of instances. Genetics • Several recurrent chromosomal abnormalities have been identified in myelodysplastic syndromes (MDS). Cytogenetic and molecular analyses are essential for establishing clonality and assessing prognosis.
Presentation • Refractory anaemia is the predominant manifestation. • Neutropenia and thrombocytopenia occur with lesser frequency. 2 Hepatosplenomegaly is rare in myelodysplastic syndromes. Peripheral blood • Cytopenias affecting one or more myeloid lineages. • Blood films may reveal macrocytes and atypical neutrophils with poorly developed nuclear segmentation and hypogranular cytoplasm. Bone Marrow • Morphological indicators of myelodysplasia may be observed in one or more myeloid lineages within the bone marrow. • Dyserythropoiesis is defined by nuclear budding, internuclear bridging, karyorrhexis, multinuclearity, nuclear hypolobulation, megaloblastic alterations, ring sideroblasts, and cytoplasmic vacuolization. • Dysgranulopoiesis is characterized by reduced size, nuclear hypolobation, irregular hypersegmentation, and cytoplasmic hypogranularity. • Dysmegakaryocytopoiesis is marked by reduced size, nuclear hypolobation, or multinucleation.
Prognosis: Survival is contingent upon various criteria, including morphological subtype, karyotype, degree of cytopenia, and age. • Low-risk variants of MDS exhibit a protracted natural history and demonstrate a minimal incidence of progression to AML. • High-risk variants are more aggressive, with numerous individuals rapidly succumbing to bone marrow loss or AML.
Definition: A collection of hematopoietic neoplasms distinguished by dysplasia in one or more myeloid cell lineages, accompanied by inefficient myelopoiesis, cytopenias, and an elevated risk of acute myeloid leukemia (AML) development.
Epidemiology • Estimated yearly incidence ranges from 3 to 5 per 100,000 individuals. • Predominantly affects older adults, with a median age of 70 years.
Aetiology • Predominantly unknown in the majority of instances. Genetics • Several recurrent chromosomal abnormalities have been identified in myelodysplastic syndromes (MDS). Cytogenetic and molecular analyses are essential for establishing clonality and assessing prognosis.
Presentation • Refractory anaemia is the predominant manifestation. • Neutropenia and thrombocytopenia occur with lesser frequency. 2 Hepatosplenomegaly is rare in myelodysplastic syndromes. Peripheral blood • Cytopenias affecting one or more myeloid lineages. • Blood films may reveal macrocytes and atypical neutrophils with poorly developed nuclear segmentation and hypogranular cytoplasm. Bone Marrow • Morphological indicators of myelodysplasia may be observed in one or more myeloid lineages within the bone marrow. • Dyserythropoiesis is defined by nuclear budding, internuclear bridging, karyorrhexis, multinuclearity, nuclear hypolobulation, megaloblastic alterations, ring sideroblasts, and cytoplasmic vacuolization. • Dysgranulopoiesis is characterized by reduced size, nuclear hypolobation, irregular hypersegmentation, and cytoplasmic hypogranularity. • Dysmegakaryocytopoiesis is marked by reduced size, nuclear hypolobation, or multinucleation.
Prognosis: Survival is contingent upon various criteria, including morphological subtype, karyotype, degree of cytopenia, and age. • Low-risk variants of MDS exhibit a protracted natural history and demonstrate a minimal incidence of progression to AML. • High-risk variants are more aggressive, with numerous individuals rapidly succumbing to bone marrow loss or AML.
0 Comments
